Rising long term bond yields have pushed borrowing costs higher, which puts pressure on many growth stocks that rely heavily on cheap debt. That makes financially healthier Australian growth stories more interesting right now. This screener focuses on businesses where analysts see strong earnings growth potential and balance sheets that can better handle higher rates. In this article, you will see three of the strongest candidates from that group.
The three Australian stocks highlighted below are only a sample of the opportunities that fit this healthier growth profile. The full screen surfaced 92 more companies with similarly interesting earnings stories that are not covered here.
If you want to go straight to the source and work through the full list yourself, use the Healthy high growth potential screener to identify, filter, and analyze the candidates that best match your own convictions.
4DMedical (ASX:4DX)
4DMedical focuses on non invasive respiratory imaging, using tools like the XV Scanner and CT:VQ software to measure lung function, and currently earns about A$7 million from lung function analysis, giving it a market value of roughly A$2.4b.
4DMedical fits the Healthy high growth potential theme because its lung imaging platform directly targets a large respiratory care need while sitting on a balance sheet that analysts view as capable of supporting expansion. That sets the stage for one contract in particular to matter.
"Partnership with Philips promised a $10Million USD minimum order commitment contract over the next 2 years starting December 2025 (over 2026 and 2027). Philips has added 4DMedicals CT:VQ technology as an official product on their catalog in North America."
What happens if a single assumption about how quickly hospitals adopt 4DMedical's software shifts, for better or worse, could reshape that growth path.
That adoption swing is exactly what the full narrative for 4DMedical unpacks, showing how contract timing, cash burn, and hospital behavior could either accelerate or stall 4DMedical's trajectory.
Neuren Pharmaceuticals (ASX:NEU)
Neuren Pharmaceuticals develops treatments for neurological disorders, with its approved Rett syndrome therapy DAYBUE anchoring the Healthy high growth potential theme. The company generates around A$69 million from commercial products and has a market value of about A$2.6b.
Neuren Pharmaceuticals fits this Healthy high growth potential screen because DAYBUE already brings in real cash from Rett syndrome. At the same time, a broader pipeline of NNZ-2591 programs creates a second leg of potential earnings expansion if things go right.
"The expectation of increased diagnosed population and patient uptake of DAYBUE in the U.S. indicates potential revenue growth with more patients getting access to the drug."
Any change in a single assumption about how U.S. treatment uptake translates into long term pricing and margin power, whether higher or lower, could have a significant impact.
That pricing and margin question is where the story really starts to get interesting, and the full narrative for Neuren Pharmaceuticals maps how accelerating uptake and pipeline risks could reshape expectations.
Megaport (ASX:MP1)
Megaport runs a Software Defined Network that lets enterprises switch on data center to cloud and cloud to cloud connections as needed. This is exactly the type of recurring, high margin connectivity business this Healthy high growth potential screen is built around.
Megaport generates about A$198 million from The Americas, A$70 million from Asia Pacific, and A$44 million from Europe through its on demand interconnection services, and the stock has a market value near A$4.6b.
For this screener, Megaport matters because its SDN and on demand interconnection platform turns rising cloud and AI traffic into usage based revenue, giving the business direct exposure to the earnings growth analysts are focusing on.
"Skyrocketing enterprise bandwidth, surging AI/cloud adoption, and the rapid proliferation of data centers are combining to create secular tailwinds. Megaport's automation, global reach, and software-defined architecture give it significant ability to be the connectivity backbone for AI factories, data-native SaaS, and hybrid enterprise networks, pointing to durable double-digit top-line expansion."
What really determines how powerful that story becomes is how one pressure on future profitability resolves in the background over the next few years.
That profitability pressure is exactly what the full narrative for Megaport unpacks. It reveals where Megaport could see earnings accelerate, cost friction ease, or growth expectations decouple from current sentiment.
Seeking Fresh Alternatives Before They Fly?
Fresh opportunities move fast, and the best setups rarely stay under the radar for long. Before the next breakout gathers momentum and ideal entries get caught, consider your options now.
- Scout cash flow machines with strong balance sheets using the curated list of solid balance sheet and fundamentals (12 results) before others notice the quality behind quieter share prices.
- Explore potential AI-related ideas by scanning 87 AI infrastructure stocks while infrastructure builders are still priced for current capacity.
- Prepare for possible changes in the metals space using the hand picked 36 best rare earth metal stocks and identify producers before demand headlines shape wider attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com